Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnolia: abelacimab vs dalteparin for cancer-associated VTE in GI/GU cancers
NL-OMON59745Phase 3Completed
- Sponsor
- Anthos Therapeutics
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of abelacimab, sponsored by Anthos Therapeutics. Started Dec 2022; status: completed.
02
Drugs
abelacimab
Beyond the preview
Go deeper on NL-OMON59745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59745.